Antiviral Drugs Industry News & Blogs

Industry News & Blogs

Herpes Cold Sore Product Xerclear® Launching for OTC Use in Europe | PRLog
www.prlog.org | Feb 12, 2012
Herpes Cold Sore Product Xerclear® Launching for OTC Use in Europe. The CBCD just learned that Medivir AB has announced that its cold sore product Xerclear®, is being launched for over-the-counter use by its partner GlaxoSmithKline in Europe. - PR11796726

Bristol Myers Squibb Company Hepatitis C Pills
www.biospace.com | Jan 19, 2012
PRINCETON, N.J.----Bristol-Myers Squibb Company today announced the full results, published in the New England Journal of Medicine, from a Phase II

Gilead Delivers With HIV Pipeline Candidate - Seeking Alpha
seekingalpha.com | Dec 6, 2011
< strong > By < a href="http://register.zacks.com/ucd/step1.php?ALERT=alpha & ADID=ALPHA_content_welcome" > Zacks.com < /a > : < /strong > < p > One of the world's largest drug makers, Gilead Sciences, Inc. ( < a href='http://seekingalpha.com/symbol/gild' title='Gilead Sciences, Inc.' > GILD < /a >

CSR and Sustainability in the News - Pharmaceutical Technology
pharmtech.findpharma.com | Sep 1, 2011
A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

In the Real Life Setting, Boosted REYATAZ® (atazanavir/ritonavir) Proves as Effective in Women
www.prweb.com | Jul 20, 2011
Boosted REYATAZ shows durable viral suppression in antiretroviral-experienced women living with HIV, in a gender-specific sub-analysis of a large retrospective cohort study.1

Bristol-Myers Squibb signs new agreement to expand access to Reyataz | Pharma Asia
www.pharmaasia.com | Jun 28, 2011
Bristol-Myers Squibb Company announced a new agreement to expand access to Reyataz (atazanavir sulfate). The immunity-from-suit agreement signed with Matrix Laboratories Limited, a Mylan Company, enables the generic company to manufacture and sell atazanavir, as well as stavudine and didanosine, in

Adjuvant interferon: extended follow-up times needed? : The Lancet Oncology
www.thelancet.com | May 23, 2011
Adjuvant interferon: extended follow-up times needed?. By - Fredrik B Thoren, Örjan Strannegård

Medical News: A Look Back at 2010 HIV/AIDS Research, a Clinical Context Report - in Clinical
www.medpagetoday.com | May 2, 2011
In this exclusive video report, Michael Smith reviews some of the most important news out of the 2010 ICAAC and IDSA Meetings with a leading expert in the field.

Hepatitis B virus reemerges with long-term nucleoside analog treatment
www.eurekalert.org | Apr 28, 2011
A recently published study revealed that virological breakthrough (VBT) is common in patients receiving nucleoside analogs for chronic hepatitis B. Nearly 40 percent of the VBTs found were not related to antiviral drug resistance. Details of this retrospective study are published in the May issue

Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data from Phase 2 Study of
www.abbott.com | Apr 4, 2011
Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C